DOSIERUNGSPLAN EINES S1P-REZEPTORAGONISTEN

European patent · EP2379069 · In force

Register entry

Publication number
EP2379069
Application number
EP09793546
Kind
European patent with effect for Switzerland and Liechtenstein
Status
In force
Specification
Granted
Filed
Dec 21, 2009
Published
Oct 26, 2011
Granted
Mar 4, 2015
Protection ends at the latest
Dec 20, 2029
Next annual fee due
Dec 31, 2026
IPC classes
A61K 31/192 (2006.01)
A61K 31/397 (2006.01)
A61K 31/401 (2006.01)
A61K 31/445 (2006.01)
A61P 37/00 (2006.01)
A61P 37/06 (2006.01)
Priority
US 139673 P 22.12.2008
EP 09167209 04.08.2009
PCT application
PCT/EP2009/067618 21.12.2009
PCT publication
WO2010/072703 01.07.2010
Filing language
English
Source
Swissreg

Supplementary protection certificates

A certificate extends the patent’s protection for a medicine or a plant protection product authorised in Switzerland.

Siponimod

C02379069/01 · Medicine · Granted · Protection from Dec 21, 2029 to Dec 20, 2034

Authorisation 67230 (Swissmedic, Oct 22, 2020)

History

What the Federal Institute of Intellectual Property published about this title, newest first.

  1. Jan 1, 2026

    Change

    Published in Swissreg on 01.01.2026

  2. Jan 1, 2025

    Change

    Published in Swissreg on 01.01.2025

  3. Jan 1, 2024

    Change

    Published in Swissreg on 01.01.2024

  4. Jan 1, 2023

    Change

    Published in Swissreg on 01.01.2023

  5. Mar 4, 2015

    Granted

    Published in Swissreg on 04.03.2015

Parties

Holder

Novartis AG

Lichtstrasse 35, 4056 Basel

Inventor

LEGANGNEUX, Eric

CH-4002 Basel

The register names each party by name and address. A holder or agent is linked to an organization where exactly one entity of the commercial register bears its name; the street of a party not so recognised is not shown here.